Literature DB >> 21073364

Aldosterone antagonists--last man standing?

Paul W Armstrong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21073364     DOI： 10.1056/NEJMe1012547

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 2.  Platt versus Pickering: what molecular insight to primary hyperaldosteronism tells us about hypertension.

Authors:  Morris J Brown
Journal:  JRSM Cardiovasc Dis       Date:  2012-09-30

Review 3.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

4.  Similar to spironolactone, oxymatrine is protective in aldosterone-induced cardiomyocyte injury via inhibition of calpain and apoptosis-inducing factor signaling.

Authors:  Ting-Ting Xiao; Yuan-Yuan Wang; Yan Zhang; Cong-Hui Bai; Xiang-Chun Shen
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.